Imagine being invited to join a clinical trial that could genuinely make a difference, but the nearest site is hours away, your work schedule is packed, and you have a family member relying on you at home. For many people that decision is not about willingness, it is about practicality. The travel alone becomes a barrier. These are the realities decentralised clinical trials are designed to change.
For years clinical research has relied on a site-led model where every assessment, questionnaire, and conversation requires an in-person visit. It is a system that works for some, but it leaves many behind. Digital tools and new operating approaches are helping the industry rethink that structure. Instead of pulling participants toward the site, decentralised trials bring the study to them.
Video consultations, home nursing visits, wearable devices, and remote assessments have widened access in ways that were not possible a decade ago. The shift accelerated during the pandemic, but it has continued because it reflects a more practical way to conduct research. This article outlines how decentralised clinical trials work, the regulatory context shaping them, common challenges, and practical design considerations for sponsors and their partners.
A decentralised clinical trial uses a combination of digital technologies and community-based services to support participation from outside a traditional trial site. This can include virtual discussions during consent, home delivery of investigational product, continuous data capture through wearables, or local sample collection. Some trials operate entirely remotely, while others follow a hybrid model that blends digital options with essential on-site assessments. The goal is to protect scientific integrity while reducing the burden placed on participants.
In practice, trials sit on a spectrum from fully site-centric designs, through hybrid models with selected remote visits or assessments, to studies that are almost entirely conducted away from the research centre. Today, most decentralised activity sits in this hybrid middle ground, anchored by an investigator site but extending participation into participants’ homes and local services.
It is useful to think of decentralisation as a set of trial elements rather than a completely separate trial type. A study may use remote consent, electronic clinical outcome assessment, telemedicine, home nursing, local laboratory testing, direct-to-patient supply, or wearable data capture while still retaining site visits for procedures that need in-person clinical oversight. This is why many decentralised clinical trial models are hybrid in practice.
Traditional site-based research assumes participants can travel regularly and fit rigid schedules into their daily lives. Many cannot. Care-giving responsibilities, mobility challenges, shift work, disability, rural location, and transport issues can all prevent people from taking part.
Decentralised clinical trials aim to reduce that burden by moving selected activities closer to the participant. Remote check-ins, digital questionnaires, local sample collection, home health visits, and connected devices can make participation more practical without removing the need for clinical oversight.
The main benefits of decentralised clinical trials usually fall into four areas:
Access and recruitment
Remote and local options can make participation more realistic for people who live far from specialist sites or cannot attend frequent visits. This can support broader recruitment, including groups that are often under-represented in research.
Retention and engagement
When participation fits more easily around daily life, participants may be more likely to remain involved and complete assessments.
Data capture
Digital tools can collect information between site visits, including patient-reported outcomes, activity measures, physiological signals, and other remote assessments. This can give study teams a more continuous view than scheduled visits alone.
Operational efficiency
Remote visits and electronic assessments can reduce some scheduling pressure and manual handling, although they also require careful planning, training, data review, and vendor oversight.
These benefits should be treated as design opportunities. A decentralised model only adds value when the selected elements fit the protocol, participant population, endpoint strategy, and the safety profile of the study.
Not every study is a good candidate for extensive decentralisation. The right model depends on what the trial needs to measure, how much clinical oversight is required, and whether remote or local procedures can be performed consistently.
A decentralised clinical trial model may be suitable when:
A more site-based model may still be needed where complex imaging, surgical procedures, specialist administration, high-risk safety monitoring, or tightly controlled sample processing is central to the trial. In many cases, the practical answer is a hybrid design: decentralise the activities that reduce burden and keep site visits for procedures that genuinely need them.
A practical readiness check can help sponsors avoid treating decentralisation as a technology decision alone. Before selecting tools or vendors, study teams should be able to answer whether each remote endpoint has a clear source, owner, collection window, review pathway and fallback option.
Electronic clinical outcome assessment, or eCOA, is a major part of many decentralised clinical trial models. It allows outcomes to be collected electronically rather than through paper forms or only during site visits. ePRO, or electronic patient-reported outcome data, is one common form of eCOA where participants record symptoms, functioning, quality of life, or other outcomes directly.
In a decentralised setting, eCOA and ePRO can support active data collection, where participants enter information into an app, web portal, or provisioned device. They can also sit alongside passive data capture, where wearables or sensors collect information such as activity, sleep, heart rate, or other physiological measures with limited participant input.
The value of eCOA in decentralised clinical trials depends on more than the technology itself. Sponsors need to define when each assessment is completed, who completed it, where it was completed, what device or platform was used, and how the result links back to the participant, visit, endpoint, and source record. Without that context, remote data may be difficult to interpret or reconcile.
In long-duration decentralised studies, ePRO can become a core route for monitoring patient-reported outcomes over time. That makes completion windows, reminders, missing data handling, review expectations, and escalation rules part of the data model rather than an afterthought.
This is often where eCOA succeeds or fails in practice. The platform may capture the response correctly, but the study still needs to define how late entries are handled, when missing data triggers follow-up, and whether a response should prompt site review, medical review or no immediate action.
Data integrity across multiple technologies remains a central concern in decentralised designs. Different platforms may store similar information in incompatible formats or without the context needed for analysis. Sponsors can reduce this risk by defining common data models early, agreeing standard mappings across vendors, and using near real-time reconciliation to detect discrepancies before they affect decision-making.
Principal investigator oversight is another recurring challenge when activities move away from the physical site. Without clear structures, accountability for safety reviews, protocol adherence, and follow-up can become blurred. Defining delegated tasks in study documentation, using structured teleconsultations for key visits, and maintaining regular safety reviews and monitoring meetings help keep investigators firmly in control of decentralised elements.
Licensure, logistics, and product handling can also become more complex when investigational product is shipped directly to participants or administered at home. Planning country-specific licensure requirements, arranging temperature-controlled shipping where needed, and providing clear, simple instructions for storage and handling at home all help maintain compliance and protect product quality.
Finally, the digital divide risks excluding people with limited access to technology, connectivity, or language support. To keep participation broad and inclusive, teams can offer device provision where appropriate, build offline or low-bandwidth options, provide local visit alternatives for critical procedures, and design multilingual, low-complexity interfaces that are easier to use in everyday life.
Other challenges include privacy, cybersecurity, participant identity management, inconsistent user training, software updates, device loss or malfunction, and unclear escalation pathways when a remote result suggests a safety concern. These are not reasons to avoid decentralisation, but they do need to be planned before the first participant is enrolled.
Quanticate supported clinical data management for a large-scale Phase 3 long-term extension dermatology study in moderate-to-severe atopic dermatitis. The study relied on decentralised patient participation, home-based administration and patient-reported outcomes, which created challenges around adherence oversight, data completeness and consistent safety and efficacy reporting over an extended duration.
The work included customised EDC and ePRO systems, real-time data availability, monitoring, adherence oversight, validation and statistical quality control. It also required integration of legacy data from multiple prior Phase 2 and Phase 3 studies, preserving longitudinal continuity across the broader clinical programme.
Data management is one of the areas where decentralised clinical trials can become more complex than traditional site-led delivery.
To keep the data usable, sponsors should document:
For long-term extension studies or programmes that draw on earlier trials, data management also needs to protect continuity across phases and timepoints. Legacy data integration, consistent mapping and clear provenance are especially important where decentralised participation sits within a wider clinical development programme. This makes data management the control point for DCT reliability.
Sponsors remain responsible for trial quality, vendor oversight, monitoring arrangements, system suitability, data protection, and ensuring that the protocol describes decentralised elements clearly. Investigators remain responsible for participant safety, protocol conduct, review of relevant trial data, and oversight of delegated activities, including those performed by local healthcare professionals, home health providers, or other third parties.
Delegation should be documented before activities begin. Study teams should define which tasks can be performed remotely, which require investigator review, how safety signals are escalated, how protocol deviations are handled, and how local providers are trained. This is especially important when routine care and trial-specific activities occur in the same local setting.
Where investigational product is supplied away from the main site, the protocol and operational documents should address shipment, temperature control, receipt confirmation, storage instructions, dosing support, return, disposal, and emergency contact routes. Participants should receive instructions that are clear enough to follow at home, and the investigator should retain appropriate oversight of use and safety.
For some products, local administration by a trained healthcare professional may be appropriate. For others, site-based administration remains the safer and more controlled option. The model should follow the product risk, not the other way around.
A decentralised operating model connects core clinical systems with participant-facing tools and supporting services. Typical components include electronic data capture (EDC) for investigator-entered data, eCOA/ePRO platforms for patient-reported outcomes (PROs), eConsent for remote information and consent discussions, telehealth solutions for virtual visits, remote patient monitoring and wearables for continuous data, interactive response technologies (IRT) for randomisation and supply, and eTMF for trial master documentation.
Depending on the study, the operating model may also include home health providers, local healthcare professionals, local laboratories, participant portals, clinical trial management systems, risk-based quality management tools, imaging vendors, and direct-to-patient supply providers.
These systems must be tied together through data flows, role-based access, audit trails, and validation aligned to requirements such as 21 CFR Part 11 and GDPR. Clear vendor oversight and change management processes help ensure that updates to any one component do not compromise participant safety.
Sponsors begin by assessing feasibility. This includes digital readiness, the complexity of required procedures, and the balance between remote and on-site activities. Selecting vendors with proven interoperability and clear user support is crucial.
A practical feasibility review should ask whether each decentralised element reduces burden without weakening safety oversight, endpoint quality, or protocol adherence. It should also consider whether sites have the capacity, training, and systems to manage remote activity alongside traditional visit work.
Decentralised design should happen early enough to shape the protocol, data management plan, vendor model, monitoring plan, and participant support model. Adding decentralised tools late in study set-up can create avoidable operational and data quality problems. For long-duration studies, this planning also needs to account for protocol amendments, evolving study requirements and operational continuity.
Regulators now provide clearer expectations for decentralised approaches.
The FDA’s 2024 final guidance on clinical trials with decentralised elements covers remote assessments, telemedicine, digital technologies, and home delivery of investigational product. It emphasises safety oversight and data reliability.
The EMA’s 2022 recommendations focus on feasibility, consistent procedures, participant protection, and data privacy.
ICH E6(R3) supports modern trial conduct through risk-based, proportionate quality management and clearer expectations for data governance, systems, responsibilities, and participant protection. It should be treated as part of the wider GCP framework rather than as DCT-specific guidance.
In the UK, sponsors should align decentralised trial methods with current HRA and MHRA expectations, including risk assessment, participant information and consent, data flow mapping, and applicable clinical trial authorisation requirements.
Across regions the underlying expectations are similar. Trials must have validated systems, clear responsibilities, secure data handling, and transparent protocols for activities that occur outside traditional sites.
The key regulatory message is that decentralised elements do not lower the standard expected of a clinical trial. Sponsors still need participant protection, reliable data, appropriate monitoring, clear delegation, documented data flows, and traceable decision-making.
Decentralised trials work best when remote, local and site-based elements are selected early, documented clearly, and supported by the right data and oversight model.
Quanticate’s clinical data management team specialises in harmonising remote datasets, applying CDISC-aligned standards, and delivering continuous quality monitoring across decentralised studies. If you want to explore how we can support the operational and data strategy of your decentralised trial, request a consultation below.
Should there be a central location or physical site in a decentralised clinical trial?
Some trials operate fully remotely while others retain a primary site for complex assessments or oversight. Hybrid models provide the flexibility needed for most therapeutic areas.
How is remote data collected in decentralised clinical trials?
Remote data can be captured through wearables, mobile apps, telemedicine consultations, home health services, and electronic questionnaires.
What's the difference between a decentralised clinical trial and a virtual clinical trial?
A virtual trial is completely remote. A decentralised trial is broader and includes any design that moves part of the participant journey away from the site. Most decentralised studies use a hybrid structure rather than a fully virtual one.